Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 11/20 | 0.68 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.68 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15790545 | 1.00 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Bromide SCHEMBL27157764 | 0.98 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Bromide SCHEMBL15775912 | 0.98 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Piperazine SCHEMBL1203054 | 0.94 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL26288696 | 0.85 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13589901 | 0.85 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5497908 | 0.85 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7241098 | 0.85 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Bromide SCHEMBL5075013 | 0.84 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL24028165 | 0.83 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240122951-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATING ACTIVITY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN WITH SMALL MOLECULE LIGANDS | SRX CARDIO, LLC | 2024-04-18 | — | — | US | disclosed |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | SRX CARDIO, LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210275551-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | SRX CARDIO, LLC | 2021-09-09 | — | — | US | disclosed |
| US-11026957-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | SRX CARDIO, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200253995-A1 | METHOD TO TREAT HYPERCHOLESTEROLEMIA BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | SRX CARDIO, LLC | 2020-08-13 | — | — | US | disclosed |
| US-10688114-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SXR Cardio, LLC (US) | 2020-06-23 | — | — | US | disclosed |
| US-10307433-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SRX CARDIO, LLC (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180303855-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC | 2018-10-25 | — | — | US | disclosed |
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SRX CARDIO, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2017-08-31 | — | — | US | disclosed |
| WO-2016029037-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2016-02-25 | — | — | WO | disclosed |
| EP-2215093-B1 | NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2011-12-14 | — | — | EP | disclosed |
| EP-2215093-A1 | NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009050236-A1 | NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050236-A1 | NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| EP-1757608-A1 | New benzazepine derivatives, medicaments containing the same and their use in the preparation of medicaments | Sanochemia Pharmazeutika Aktiengesellschaft (AT) | 2007-02-28 | — | — | EP | disclosed |
| US-7101890-B2 | Benzazepine derivatives, drugs containing these and use of the same for producing drugs | SANOCHEMIA LTD. (MT) | 2006-09-05 | — | — | US | disclosed |
| US-20040067974-A1 | New benzazepine derivatives, drugs containing these and use of the same for producing drugs | SANOCHEMIA LTD. (MT) | 2004-04-08 | — | — | US | disclosed |
| US-6638925-B2 | In particular benzofuro(3a,3,2,ef)(2)benzazepin; treatment of Alzheimer's disease and related dementia conditions, Langdon-Down syndrome | SANOCHEMIA LTD. (MT) | 2003-10-28 | — | — | US | disclosed |
| US-20030092700-A1 | BENZAZEPINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME AND THEIR USE TO PREPARE MEDICAMENTS | SANOCHEMIA LTD. (MT) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | PCSK9, LDLR, PCSK7 | CHRNB2 2985/4885CHRNA4 3587/4885CHRNB4 3052/4885 |
| US-10307433-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | CHRNB2 3002/4885CHRNA4 3580/4885CHRNB4 3059/4885 |
| US-20180303855-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | PCSK9, LDLR, PCSK7 | CHRNB2 3002/4885CHRNA4 3580/4885CHRNB4 3059/4885 |
| US-20030092700-A1 | BENZAZEPINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME AND THEIR USE TO PREPARE MEDICAMENTS | PSEN2, BACE2, BACE1 | CHRNB2 108/4885CHRNA4 354/4885CHRNB4 170/4885 |
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | CHRNB2 2985/4885CHRNA4 3587/4885CHRNB4 3052/4885 |
| US-20210275551-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | PCSK9, LDLR, PCSK7 | CHRNB2 3597/4885CHRNA4 3803/4885CHRNB4 3588/4885 |
| US-20240122951-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATING ACTIVITY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN WITH SMALL MOLECULE LIGANDS | PCSK9, LDLR, PCSK7 | CHRNB2 3533/4885CHRNA4 3703/4885CHRNB4 3512/4885 |
| US-20040067974-A1 | New benzazepine derivatives, drugs containing these and use of the same for producing drugs | BACE2, PSEN2, BACE1 | CHRNB2 84/4885CHRNA4 153/4885CHRNB4 92/4885 |
| US-20200253995-A1 | METHOD TO TREAT HYPERCHOLESTEROLEMIA BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | PCSK9, LDLR, PCSK7 | CHRNB2 3363/4885CHRNA4 3447/4885CHRNB4 3232/4885 |
| US-11026957-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | PCSK9, LDLR, PCSK7 | CHRNB2 3579/4885CHRNA4 3794/4885CHRNB4 3574/4885 |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | PCSK9, LDLR, PCSK7 | CHRNB2 3579/4885CHRNA4 3794/4885CHRNB4 3574/4885 |
| US-10688114-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | CHRNB2 3002/4885CHRNA4 3580/4885CHRNB4 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.